<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572650</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2117</org_study_id>
    <nct_id>NCT00572650</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients</brief_title>
  <official_title>An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of LAF237 and Its Metabolites in Mild Renal Impaired Patients Compared to Age, Sex and Weight-matched Healthy Volunteers Following Daily Doses of 100 mg LAF237 for 14 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics of vildagliptin (LAF237) and its metabolites in
      patients with mild renal impairment compared to their sex, age and weigh based healthy
      volunteer counterparts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measures</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability measures</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <description>16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 75 years of age (inclusive).

          -  Male, non-fertile female or female of childbearing potential using a medically
             approved birth control method.

          -  Body mass index (BMI) ≤42 kg/m2 (inclusive) at Screening.

          -  Able to provide written informed consent prior to study participation.

          -  Able to communicate well with the investigator and comply with the requirements of the
             study.

        For renal insufficient patients only

          -  Patients must have stable renal disease without evidence of renal progressive disease

          -  If patient is diabetic, must be treated with standard anti-diabetic therapy andmust
             agree to continue their anti-diabetic therapy throughout the duration of the study.

          -  If patient is diabetic, must be on a stable dose of standard anti-diabetic therapy or
             diet and exercise regimen over the past 4 weeks prior to Screening.

        For healthy subjects only

          -  No current significant medical conditions as determined by history and physical.

          -  A serum creatinine with a calculated CrCl of &gt;80 ml/min.

          -  Matched to renal impaired patients (Group A) undergoing study by age (±5 years), sex
             and weight (±10% BMI).

        Exclusion Criteria:

        Subjects meeting any of the following criteria during screening or baseline evaluations
        will be excluded from entry into or continuation in the study:

          -  Pregnant or lactating female.

          -  A history of certain disorders as specified in the protocol.

          -  Subjects that have been enrolled in a LAF237 (vildagliptin) study or other DPP-4
             inhibitor studies six months prior to Baseline.

          -  History of renal transplant at any time in the past and on immunosuppressant therapy.

          -  Acute infections which may affect blood glucose control within 4 weeks prior to
             Screening and other concurrent medical condition that may interfere with the
             interpretation of efficacy and safety data during the study.

          -  Certain electrocardiogram (ECG) abnormalities:

          -  Malignancy including leukemia and lymphoma (not including basal cell skin cancer)
             within the last 5 years.

          -  Liver disease such as cirrhosis or positive hepatitis B and C.

          -  Any alcohol related hepatic disease.

          -  Patients undergoing any method of dialysis (hemodialysis or peritoneal dialysis)

          -  Concurrent medical condition that may interfere with the interpretation of safety and
             tolerability data during the study.

          -  Use of certain medications as specified in the protocol.

          -  Laboratory abnormalities as defined by the protocol

          -  History of active substance abuse (including alcohol) within the past 2 years.

          -  Smokers defined as any subject who reports heavy cigarette use (i.e., 10 or more
             cigarettes per day). Urine cotinine will also be measured and recorded at Screening
             and Baseline.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NOVARTIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>April 30, 2012</last_update_submitted>
  <last_update_submitted_qc>April 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2012</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Type-2 diabetes, DPP-4 inhibitor, vildagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

